Navigation Links
Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc.
Date:9/12/2011

WEST BEND, Wis., Sept. 12, 2011 /PRNewswire/ -- Frontage Laboratories, Inc., a global full-service Clinical Research Organization with facilities in the US and China, and Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical Pharmacology Unit, ECG Core Lab, and Medical Device Manufacturer have entered into a strategic partnership agreement.  This synergistic and cost-effective partnership establishes a global footprint by combining Frontage's presence in China and its expertise in drug formulation and Bioanalytical analysis, along with Spaulding Clinical's Cardiac Safety and fully-automated Clinical Pharmacology facility.

As part of the relationship, Spaulding Clinical will perform all intense electrocardiographic studies in its facility and provide ECG Core Lab services on behalf of Frontage.  In return, Frontage will provide bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding Clinical, as well as serve as one of the clinical sites for Spaulding Clinical clients in China.

"Throughout the due diligence process, we were thoroughly impressed with the innovative, quality-focused clinical conduct we witnessed at Spaulding," states Song Li, PhD, CEO and Chairman of Frontage Laboratories, Inc.  "The collaboration with Spaulding Clinical will enable Frontage to better service our current and potential clients in a more comprehensive approach, especially in the areas of cardiac safety, thorough QT, and ECG Core Lab."

Randy Spaulding, CEO and Founder of Spaulding Clinical, states, "This collaboration represents another step forward in meeting our strategic objectives of providing the highest quality global clinical development facilities to our clients interested in accelerating drug development.  Together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China."

Jason Wu, MD, Sr. VP and General Manager of Frontage Clinical Services, states, "Spaulding's expertise in the Cardiac Safety aspects of clinical trials makes them the perfect partner to complement our clinical offering in both the US and China.  We view the Spaulding iQ Electrocardiograph as a key innovation that enables the centralization of critical cardiac safety data in a cost-effective manner – a need many of our clients have identified."

Frontage Laboratories, Inc. (www.frontagelab.com; www.frontagelab.com.cn) is a global full-service contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform. Frontage runs three Phase 1 Clinical units: a 72-bed Phase 1 Unit in Hackensack, NJ USA, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China and a-80 bed Phase 1 Unit in Changchun, Jilin Province China. Frontage has bioanalytical and CMC facilities in both the US (Bioanalytical lab in Malvern, PA; CMC facility in Exton, PA) and China (Bioanalytical lab in Shanghai; CMC facility in Beijing). The operations of biometrics and late phase services are based in both Exton, PA and Beijing, China. Frontage's preclinical animal facility is also located in Exton, PA. As a rapidly expanding CRO with a ten-year successful history of its high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.

Spaulding Clinical Research, LLC (www.spauldingclinical.com) provides Clinical Pharmacology, Cardiac Core Lab clinical research services and is a medical device manufacturer. Spaulding Clinical operates a 105-bed clinical pharmacology unit with 96-beds of Mortara telemetry in West Bend, Wisconsin. The facility is paperless with a phase I Electronic Data Capture system and bi-directional interfaces to safety lab, bedside devices and telemetry. As a Phase I-IV Core ECG Laboratory provider, Spaulding offers the complete suite of equipment provisioning and electrocardiograph over-reading services with state-of-the-art technologies, including the proprietary Spaulding iQ Electrocardiograph, and expertly trained cardiologists and project managers.


'/>"/>
SOURCE Spaulding Clinical Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients
2. Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
3. Spaulding Clinical Honored at BizTech Conference
4. Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant
5. Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
7. Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
8. Roche Starts Early Stage Clinical Trial in Down Syndrome
9. Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference
10. Cardicas Cardiac Anastomosis Device Featured in Clinical Presentation on Robotic Cardiac Bypass Procedures
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
Breaking Medicine News(10 mins):